Trials / Terminated
TerminatedNCT00165880
An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine
An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Metastatic Breast Cancer Patients Following Prior Anthracycline and Taxane Therapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Eisai Limited · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The overall purpose of this study is to compare the efficacy, safety and tolerability of indisulam in combination with capecitabine (IC) versus capecitabine (C) monotherapy in patients with metastatic breast cancer who have previously been treated with an anthracycline and a taxane.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7070 |
Timeline
- Start date
- 2004-12-01
- Completion
- 2007-09-01
- First posted
- 2005-09-14
- Last updated
- 2014-07-01
Locations
33 sites across 5 countries: Germany, Italy, Russia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00165880. Inclusion in this directory is not an endorsement.